title: Effect of glycemic control on growth hormone and IGFBP-1 secretion in patients with type I diabetes mellitus.
abstract: Growth hormone (GH) secretion disorders have been reported in poorly controlled type I diabetes mellitus patients. Our work was aimed to evaluate GH secretion in 9 type I young diabetes mellitus patients as well as the low molecular weight IGF-binding protein secretion (IGFBP-1) in 5 of them. The patients did not show any signs of malnutrition or neurovascular complications, neither were they on any medication except for insulin. The study protocol included blood samples collection during a 24-h period for measurement of glucose, glycated hemoglobin, GH IGF-I and IGFBP-1 levels under two situations: on poor glycemic control and after 2-3 months on better control through systematic diet, low in carbohydrates and increase in insulin dosage. GH secretion data were analyzed by Cluster algorithm for pulsatility parameters; for rhythm assessment Cosinor method was used. The first study (poor control) reported significant increase of GH maximal and incremental amplitude and duration pulse values, when compared to the second study (better control). Mean 24-h secretion values as well mean GH for interpulse intervals (valleys) decreased, although not statistically significant. The fraction of pulsatile GH/24 h GH did not change significantly with better glycemic control. No changes in pulse frequency were observed. Mean IGF-I concentrations were significantly higher when patients were on better glycemic control. An ultradian variation for GH secretion was noticed in the first study (poor control) and a circadian variation in the second one (better control). IGFBP-1 analysis showed significant decrease of the mean 24-h values under better glycemic control. Linear regression analysis demonstrated a correlation between IGFBP-1 levels and fasting glucose levels. A circadian variation was present in IGFBP-1 secretion, irrespective of glycemic control. Therefore, we concluded that for type I diabetic patients: 1. GH secretion is increased on poor control, through maximal, incremental amplitude and pulse duration values; 2. IGFBP-1 values were significantly reduced and IGF-1 levels significantly higher after better glycemic control; 4. GH ultradian secretion is reported on poor control, and circadian on the better one, 5. IGFBP-1 circadian secretion occurred irrespective of glycemic control.
authors.affiliation: Endocrine Section Hospital das Clínicas, University of São Paulo School of Medicine, Brazil.
authors.forename: L R
authors.initials: LR
authors.lastname: Salgado
authors.forename: M
authors.initials: M
authors.lastname: Semer
authors.forename: M
authors.initials: M
authors.lastname: Nery
authors.forename: M
authors.initials: M
authors.lastname: Knoepfelmacher
authors.forename: A C
authors.initials: AC
authors.lastname: Lerário
authors.forename: G
authors.initials: G
authors.lastname: Póvoa
authors.forename: S
authors.initials: S
authors.lastname: Jana
authors.forename: S M
authors.initials: SM
authors.lastname: Villares
authors.forename: B L
authors.initials: BL
authors.lastname: Wajchenberg
authors.forename: B
authors.initials: B
authors.lastname: Liberman
authors.forename: W
authors.initials: W
authors.lastname: Nicolau
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism*; D002648:Child; D002940:Circadian Rhythm; D015331:Cohort Studies; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000378:metabolism / Q000628:therapy; D004032:Diet / Q000592:standards; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D019382:Human Growth Hormone / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000627:therapeutic use; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000097:blood* / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D019382:Human Growth Hormone; D007328:Insulin; D018970:Insulin-Like Growth Factor Binding Protein 1; D007334:Insulin-Like Growth Factor I